Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2008

View Archived Issues

Manhattan successfully completes pre-IND meetings with FDA for Altoderm and Altolyn

Recent patents impart new oncolytic agents

FDA extends review period by three months for additional indication for antibiotic Doribax

AlphaMed successfully expresses a humanized version of alpha 1- antitrypsin

Pharmion's shareholders approve USD 2.9 billion acquisition of company by Celgene

ProStrakan receives Swedish marketing authorization for Rapinyl in breakthrough cancer pain

Recent UCB and Pierre Fabre patents report new compounds for treating neurological disorders

Novel therapeutic agents for gastrointestinal disorders described in recent patent literature

Beneficial effect of beclomethasone seen in patients with GI graft-versus-host disease

Favorable impact on survival seen with Neuradiab in malignant glioma

7TM enters metabolic disorder drug discovery collaboration with Dr. Reddy's

Anesiva submits sNDA for Zingo for needle insertion pain in adults

GSK cervical cancer candidate vaccine demonstrates long-term protection

KaloBios initiates phase I/II trial of KB-002 in persistent asthma

Neuroprotective synergy seen with lithium and valproic acid in vitro

Evidence links 5-HT2A-mGluR2 complex to psychosis

Zeria and Astellas co-develop and co-market Z-338 for functional dyspepsia in Japan

Oxford Biomedica completes enrolment in phase III TRIST study of Trovax in renal cancer

Lilly terminates Air insulin program for type 1 and type 2 diabetes

BioCancell submits pre-IND application to FDA for phase I clinical trials of BC-819 in cancer

Positive results from clinical phase I study of PL-3994 in congestive heart failure

Progen begins global phase III study of PI-88 in post-resection liver cancer

Genitope suspends development of MyVax personalized immunotherapy

Bionomis begins dose-finding preclinical study of its anti-anxiety candidate BNC-210

Avant completes merger of wholly owned subsidiary Callisto into Celldex

Sareum initiates in-house drug discovery program targeting the fatty acid synthase enzyme

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...